DEC 23, 2018 11:22 PM PST

Buruli ulcer: promising drug for a forgotten disease

WRITTEN BY: Nouran Amin

One of the most forgotten and neglected diseases is Buruli ulcer, a debilitating and stigmatized condition affecting primarily children in West and Central Africa. Buruli ulcer is caused by the bacterium Mycobacterium ulcerans and results in devastating skin lesions leading to permanent disfigurement and long-term disabilities.

Treatment for the disease considers surgical removal of skin lesions as well as antibiotics involving the combination of oral rifampicin and injected streptomycin. However, these treatments come with many limitations. For one, surgery is often not an accessible option especially in in low-income areas. Furtherer, administration of antibiotics requires daily visits to a health center and antibiotic use is often plagued with great side-effects resulting such as hearing loss in over 20% of treated patients. These challenges are pushing researchers to seek safer, accessible, and effective treatment options.

Now, in a study published in Nature Communications, researchers have developed a promising compound against Buruli ulcer. The compound, referred to as Q203 (an imidazopyridine amide), was concluded to be highly effective against Buruli ulcer during in vitro and in vivo studies.

"We were very surprised when we saw this high activity. We had previously screened hundreds of compounds that were originally intended for TB drug development and none of the others showed promising activity against Mycobacterium ulcerans," said Gerd Pluschke, Head of the Molecular Immunology Unit at Swiss TPH. "Q203, however, is even more effective against Buruli ulcer than the current most active antibiotic rifampicin. Such a new and exquisitely effective drug combined with a second antibiotic may result in a considerably shorter oral treatment regimen with fewer adverse side effects."

A promising new drug candidate may improve treatment options of Buruli ulcer patients.

Credit: Hubert Vuagnat via Swiss Tropical and Public Health Institute

What makes Q203 very advantageous for treatment is it has already been tested in a phase I clinical trial for Tuberculous. "That means that as soon as funding can be secured, we will directly test the new compound in Buruli ulcer patients in a phase II trial," says Pluschke.

Source: Swiss Tropical and Public Health Institute

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
Treating Malaria: Molecular Understanding of Drug Interactions
Crystallization is a process central to drug development that despite centuries of facilitating a particular method, chemists are still learning how to gra...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
FEB 21, 2020
Health & Medicine
FEB 21, 2020
Should You Really be Scared of the Coronavirus?
As of February 21st, the death toll for coronavirus reached 2,250, 55,707 currently infected, of which 12,066 (22%) are in a serious or critical condition....
MAR 18, 2020
Genetics & Genomics
MAR 18, 2020
Finding a Treatment for Fetal Alcohol Spectrum Disorder
When developing fetuses are exposed to any amount of alcohol, they are at risk for a variety of irreversible birth defects....
MAR 14, 2020
Drug Discovery & Development
MAR 14, 2020
Mental Heath Implications of a Controversial Acne Drug
Isotretinoin is a highly effective marketed treatment for acne that has long been believed to have an association with teen suicide and depression. Now, a ...
MAR 16, 2020
Drug Discovery & Development
MAR 16, 2020
Understanding How an Obesity-Treating Drug Functions
Liraglutide is a drug targeted to help treat obesity by suppressing appetite, thus making the patient lose weight. However, up until now research has not d...
Loading Comments...